NexImmune (NEXI)
(Delayed Data from NSDQ)
$3.26 USD
-0.17 (-4.96%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.33 +0.07 (2.15%) 7:46 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for NexImmune, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 35 | 82 | 5 | 10 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 4 | 3 | 1 |
Total Current Assets | 5 | 37 | 86 | 8 | 11 |
Net Property & Equipment | 1 | 4 | 4 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 0 | 0 | 0 | 0 |
Total Assets | 9 | 43 | 91 | 11 | 14 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 19 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 7 | 6 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 3 | 0 |
Total Current Liabilities | 5 | 10 | 7 | 27 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 54 | 54 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 11 | 7 | 81 | 57 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 226 | 223 | 212 | 8 | 5 |
Retained Earnings | -223 | -190 | -128 | -78 | -48 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 32 | 84 | -69 | -43 |
Total Liabilities & Shareholder's Equity | 9 | 43 | 91 | 11 | 14 |
Total Common Equity | 4 | 32 | 84 | -69 | -43 |
Shares Outstanding | 1.00 | 0.90 | 0.90 | NA | NA |
Book Value Per Share | 3.51 | 35.89 | 93.07 | 0.00 | 0.00 |
Fiscal Year End for NexImmune, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 3 | 9 | 16 | 22 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 1 | 2 | 3 |
Total Current Assets | NA | 5 | 10 | 19 | 25 |
Net Property & Equipment | NA | 1 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 0 | 0 | 0 |
Total Assets | NA | 9 | 15 | 23 | 31 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 5 | 5 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 5 | 6 | 6 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 5 | 6 | 6 | 7 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 226 | 225 | 224 | 223 |
Retained Earnings | NA | -223 | -217 | -207 | -200 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 4 | 8 | 17 | 24 |
Total Liabilities & Shareholder's Equity | NA | 9 | 15 | 23 | 31 |
Total Common Equity | 0 | 4 | 8 | 17 | 24 |
Shares Outstanding | 1.30 | 1.00 | 1.00 | 1.00 | 1.00 |
Book Value Per Share | 0.00 | 3.51 | 8.25 | 17.00 | 23.58 |